<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation for infection in exacerbations of chronic obstructive pulmonary disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation for infection in exacerbations of chronic obstructive pulmonary disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation for infection in exacerbations of chronic obstructive pulmonary disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjay Sethi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy F Murphy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julio A Ramirez, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4181754270"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most exacerbations of chronic obstructive pulmonary disease (COPD) are due to respiratory tract infection. An important part of the evaluation is determining which patients have a treatable cause of infection and when to pursue microbiologic testing.</p><p>The role of infection in exacerbations of COPD will be reviewed here. The management of infection in exacerbations of COPD is presented separately. Precipitants, risk factors, and other interventions (eg, bronchodilators, glucocorticoids, oxygen, and mechanical ventilation) are also discussed separately. (See  <a class="medical medical_review" href="/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease"</a> and  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p class="headingAnchor" id="H779607059"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>The Global Initiative for Chronic Obstructive Lung Disease guidelines define an exacerbation of COPD as an event characterized by dyspnea and/or cough and sputum that worsens over ≤14 days, which may be accompanied by tachypnea and/or tachycardia, and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H1395695156"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>It is estimated that 70 to 80 percent of exacerbations of COPD are due to respiratory infections. The remaining 20 to 30 percent are due to eosinophilic inflammation [<a href="#rid3">3</a>], environmental pollution, nonadherence to maintenance medication, or have an unknown etiology [<a href="#rid4">4</a>]. Viral and bacterial infections cause most exacerbations, whereas atypical bacteria are a relatively uncommon cause [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H3614765631"><span class="h2">Viruses</span><span class="headingEndMark"> — </span>Viruses can be detected in one-third to two-thirds of exacerbations using culture, serology, and polymerase chain reaction (PCR)-based methods. The most common viruses associated with exacerbations of COPD are rhinoviruses [<a href="#rid7">7</a>]. Influenza, parainfluenza, coronavirus, and adenovirus are also common during exacerbations [<a href="#rid7">7-15</a>]. Respiratory syncytial virus and human metapneumovirus were more recently associated with exacerbations [<a href="#rid16">16,17</a>]. </p><p>During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, a substantial reduction in viral respiratory illness and associated hospitalizations for COPD exacerbations was seen, probably due to masking and social distancing [<a href="#rid18">18,19</a>]. Though no systematic studies are available, it is likely that SARS-CoV-2 infection could present as an exacerbation in a patient with COPD, and therefore should be in the differential diagnosis [<a href="#rid20">20</a>]. A pre-existent diagnosis of COPD does increase mortality associated with SARS-CoV-2 infection [<a href="#rid20">20</a>]. (See <a class="local">'Detection of respiratory viruses'</a> below.)</p><p>However, the detection of a virus in the sputum sample of a patient having a COPD exacerbation is relatively common and does not necessarily mean that this is the cause of the exacerbation. In fact, such viruses have been found in up to 15 percent of asymptomatic individuals with stable COPD using sensitive PCR-based assays [<a href="#rid7">7,9,13,14</a>]. Influenza virus is an exception since asymptomatic colonization is unusual.</p><p>The mechanisms by which viruses induce exacerbations have been partially elucidated. Viral infection of the airway epithelial cells induces inflammation [<a href="#rid21">21</a>]. This causes airway epithelial damage, muscarinic receptor stimulation, and induction of inflammatory mediators (eg, cytokines, chemokines) [<a href="#rid22">22</a>]. Airway eosinophilia is sometimes associated with viral-mediated exacerbations, which highlights the importance of the host response to infection and its impact on both inflammation and symptoms [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H854541689"><span class="h2">Bacteria</span><span class="headingEndMark"> — </span>Bacterial infections appear to trigger one-third to one-half of COPD exacerbations. Nontypeable <em>Haemophilus influenzae</em>, <em>Moraxella catarrhalis</em>, and <em>Streptococcus pneumoniae </em>are the bacteria most frequently isolated bronchoscopically from patients having an exacerbation of COPD  (<a class="graphic graphic_table graphicRef70203" href="/d/graphic/70203.html" rel="external">table 1</a>) [<a href="#rid23">23-29</a>]. <em>Pseudomonas aeruginosa </em>and Enterobacteriaceae are also commonly isolated, particularly from patients with severe COPD.</p><p>Exacerbations of COPD are strongly associated with acquisition of a new strain of <em>H. influenzae</em>, <em>M. catarrhalis</em>, <em>S. pneumoniae</em>, or <em>P. aeruginosa </em>[<a href="#rid29">29-34</a>]. As a result, it has been proposed that acquisition of a new bacterial strain plays a central role in the pathogenesis of an exacerbation. This hypothesis is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Exacerbations with new bacterial strains are more likely to be associated with a humoral immune response – In one study, exacerbations with a new strain of <em>H. influenzae </em>were significantly more likely to be associated with a humoral immune response than exacerbations with pre-existing strains of <em>H. influenzae </em>(61 versus 21 percent) [<a href="#rid35">35</a>]. These new antibodies were strain specific. <em>M. catarrhalis</em>, <em>S. pneumoniae, </em>and <em>P. aeruginosa </em>also induce an antibody response that is measurable following an exacerbation of COPD [<a href="#rid33">33,36-38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exacerbations with new bacterial strains are associated with a more robust inflammatory response – Exacerbations of COPD with a new strain of bacteria have been associated with more intense neutrophilic airway inflammation and systemic inflammation than exacerbations not associated with a change in pre-existing bacterial strains or recovery of pathogenic bacteria [<a href="#rid39">39</a>]. Resolution of the airway inflammation is related to eradication of pathogenic bacteria from sputum and resolution of clinical symptoms. In an animal model, new strains of <em>H. influenzae </em>that were known to be associated with COPD exacerbation caused significantly more airway neutrophil recruitment than colonizing strains of <em>H. influenzae </em>[<a href="#rid40">40</a>].</p><p></p><p>Most of the human studies were performed in patients with COPD who had chronic bronchitis because expectorated sputum could be obtained easily. Thus, the degree to which the data can be generalized to exacerbations in patients with COPD who do not have chronic bronchitis is unknown. (See  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Definitions'</a>.)</p><p>The idea that exacerbations of COPD are due to acquisition of a new strain of bacteria has largely replaced the older hypothesis that increases in the concentration of colonizing bacteria are the primary cause of exacerbations. The older theory was largely disproven by a comprehensive analysis of the relationship among sputum bacterial concentrations, exacerbation occurrence, and new pathogen acquisition [<a href="#rid41">41</a>]. The analysis demonstrated that an increase in bacterial load is not a cause of exacerbation.</p><p>Molecular diagnostics, specifically 16S ribosomal ribonucleic acid (rRNA) sequencing, have been extensively employed in the study of the airway microbiome at exacerbations and in stable COPD [<a href="#rid15">15,42-45</a>]. A reduction in diversity and an increase in <em>Proteobacteria</em> with increasing severity of COPD and at exacerbation have been consistently described. Another intriguing observation suggests that even exacerbations with a dominant pathogen could be polymicrobial. When known pathogens such as <em>H. influenzae </em>increased during acute exacerbations of COPD, closely related bacterial taxa in the phylogenetic tree were also enriched, while there was a decline in those taxa that were phylogenetically distant [<a href="#rid43">43</a>]. Though much is being learned about acute exacerbations of COPD with these new techniques, their clinical significance is not yet known.</p><p class="headingAnchor" id="H3015254386"><span class="h2">Atypical bacteria</span><span class="headingEndMark"> — </span>There are conflicting data regarding the incidence of atypical bacterial infection in patients having an exacerbation of COPD. This is related, in large part, to the varying criteria used to diagnose exacerbation and infection. The incidence of <em>Chlamydia pneumoniae</em> in exacerbations of COPD was 3 to 5 percent in studies using rigorous methodology that excluded pneumonia and defined infection as a strict fourfold increase in titer or a positive culture [<a href="#rid10">10,46,47</a>]. However, based on more recent studies of patients with community-acquired pneumonia that used molecular techniques, the incidence is likely even lower (&lt;1 percent) except in the setting of epidemics (see  <a class="medical medical_review" href="/d/html/7036.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in adults", section on 'Epidemiology'</a>). <em>Mycoplasma pneumoniae</em> and <em>Legionella </em>spp are also rare causes of COPD exacerbations.</p><p class="headingAnchor" id="H2044556288"><span class="h2">Coinfection</span><span class="headingEndMark"> — </span>Coinfection with multiple pathogens is increasingly being considered in studies looking at the pathogenesis of COPD exacerbation. Such studies categorize exacerbations of COPD due to respiratory infection as being caused by viral infection alone, bacterial infection alone, or both [<a href="#rid14">14,48,49</a>]. In one study, exacerbations were equally distributed across the three categories [<a href="#rid14">14</a>].</p><p>Coinfection appears to increase the severity of COPD exacerbations. In a study of inpatients, coinfection was associated with a greater decrement of lung function and longer hospitalization [<a href="#rid14">14</a>]. In a similar study of outpatients, coinfection was associated with more symptoms, a larger fall in the forced expiratory volume in one second (FEV<sub>1</sub>), higher bacterial loads, and systemic inflammation [<a href="#rid48">48</a>].</p><p>In a human experimental model of rhinovirus-induced exacerbations, 15 days after inoculation with rhinovirus, a majority of individuals with COPD developed secondary bacterial infection, highlighting the importance of coinfection or sequential infection in exacerbations of COPD [<a href="#rid44">44</a>]. A study employing microbiome analyses to longitudinally collected sputum samples before, at, and after exacerbations demonstrated little change in microbial community structure but increased abundance of <em>Proteobacteria</em> at the time of exacerbations [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H542575306"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2277135735"><span class="h2">General characteristics</span><span class="headingEndMark"> — </span>The three cardinal symptoms that characterize an exacerbation of COPD are [<a href="#rid1">1,50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased dyspnea</p><p class="bulletIndent1"><span class="glyph">●</span>Increased sputum volume and/or viscosity</p><p class="bulletIndent1"><span class="glyph">●</span>Increased sputum purulence</p><p></p><p>Qualitative research has highlighted the prevalence of additional symptoms of chest tightness and discomfort, sleep disturbance, anxiety, and fatigue during exacerbations [<a href="#rid51">51</a>].</p><p>Constitutional symptoms, a decrease in pulmonary function, and tachypnea are variably present during an exacerbation, but the chest radiograph is usually unchanged [<a href="#rid1">1,52,53</a>]. In the presence of severe underlying airflow obstruction, an exacerbation can cause respiratory failure and death. (See  <a class="medical medical_review" href="/d/html/122144.html" rel="external">"COPD exacerbations: Clinical manifestations and evaluation"</a>.)</p><p class="headingAnchor" id="H323706924"><span class="h2">Features that suggest bacterial infection</span><span class="headingEndMark"> — </span>Clinical indicators of potential bacterial infection include more severe COPD (eg, forced expiratory volume in one second [FEV<sub>1</sub>] &lt;50 percent of predicted) and sputum purulence as part of the exacerbation. In one study of 40 patients with COPD exacerbations in whom bronchoscopy was performed, more patients with purulent sputum had bronchial infection than patients with mucoid sputum (77 versus 6 percent) [<a href="#rid54">54</a>]. In a separate study, sputum purulence correlated with increased airway bacteria concentrations and sputum neutrophilia [<a href="#rid55">55</a>]. Based on these observations, we believe that sputum purulence is an important, but not absolute, indicator of bacterial infection in patients with an exacerbation of COPD.</p><p>Another reliable clinical predictor of bacterial exacerbation is the Anthonisen criteria (cardinal symptoms of increased dyspnea, sputum volume, and sputum purulence) where the probability of bacterial exacerbation in type 1 and 2 exacerbations (three or two cardinal symptoms present, respectively) is 80 and 35 percent, respectively, whereas it is only 6 percent in type 3 exacerbations (one cardinal symptom present) [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H3983253368"><span class="h1">EVALUATION FOR INFECTION</span><span class="headingEndMark"> — </span>While bacterial and viral infections are common causes of COPD exacerbations, determining which patients have a treatable infectious cause of their exacerbation can be difficult. Precise knowledge of the presence and type of infecting organism, when available, enables antibiotic therapy to be targeted to those who are most likely to benefit. </p><p class="headingAnchor" id="H1950360483"><span class="h2">When to obtain sputum studies</span><span class="headingEndMark"> — </span>For most patients, obtaining sputum Gram stain and culture for microbiologic diagnosis is not necessary and not recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. The diagnostic accuracy of sputum cultures is not high, and the turnaround time is often too long to inform clinical decision-making [<a href="#rid1">1,56</a>].</p><p>However, for some patients, pursuing a microbiologic diagnosis is appropriate and we generally obtain sputum Gram stain and culture in the following patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with risk factors for </strong><strong><em>Pseudomonas</em></strong><strong> infection</strong> – Risk factors for <em>Pseudomonas </em>infection include recent hospitalization (≥2 days' duration during the past 90 days), frequent administration of antibiotics (≥4 courses within the past year), advanced COPD (FEV<sub>1</sub> &lt;30 percent of predicted), isolation of <em>P. aeruginosa </em>during a previous exacerbation, <em>Pseudomonas</em> colonization during a stable period, and systemic glucocorticoid use  (<a class="graphic graphic_table graphicRef126162" href="/d/graphic/126162.html" rel="external">table 2</a>) [<a href="#rid1">1,57,58</a>].</p><p></p><p class="bulletIndent1">In contrast with <em>H. influenzae</em>, <em>M. catarrhalis</em>, and <em>S. pneumoniae</em>, which are difficult to isolate from sputum cultures, <em>Pseudomonas </em>spp can be easily recovered from expectorated sputum obtained before initiating therapy. In addition, the susceptibility pattern of <em>Pseudomonas</em> is unpredictable, making the susceptibility results important for guiding the choice of antibiotic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with failure to improve on initial empiric antibiotics</strong> – The GOLD guidelines suggest that sputum Gram stain and culture may be helpful in patients who are strongly suspected of having a bacterial infection but fail to respond to initial antibiotic therapy [<a href="#rid1">1</a>]. However, even these cultures should be interpreted with caution because of their unreliability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospitalized patients, particularly those with impending or actual acute respiratory failure due to an exacerbation of COPD</strong> – We obtain a Gram stain and sputum culture in these patients even in the absence of clear risk factors for <em>Pseudomonas</em> infection. Gram stain and culture showing a likely pathogen in large concentrations generally reflects the etiologic agent.</p><p></p><p>The evidence demonstrating the limited utility of routine sputum Gram stain and culture includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Gram stain and culture of expectorated sputum yield similar results during exacerbations and stable disease [<a href="#rid8">8</a>]. In other words, they do not distinguish between true pathogens and colonizing flora. The molecular testing studies cited in the preceding section showed that newly acquired bacterial strains are often associated with exacerbations, but identification of these strains requires sequential cultures and specialized tests that are not available for routine clinical use [<a href="#rid41">41</a>] (see <a class="local">'Bacteria'</a> above). Additional supporting evidence is the presence of a likely pathogen seen on Gram stain and recovered from culture with heavy growth. Also, the failure to grow an easily cultured pathogen such as gram-negative bacilli or <em>S. aureus</em> from a purulent pretreatment specimen is evidence against their role in the exacerbation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common bacterial pathogens (<em>H. influenzae</em>, <em>M. catarrhalis</em>, <em>S. pneumoniae</em>) are frequently difficult to isolate in sputum, which increases the likelihood of a false-negative result. In one study that collected sequential sputum cultures from patients with stable COPD, molecular typing revealed that apparently identical bacterial strains of <em>H. influenzae </em>were intermittently recovered, suggesting that false-negative culture results were common [<a href="#rid59">59</a>]. Support for this hypothesis was provided by the observation that strain-specific <em>H. influenzae </em>deoxyribonucleic acid (DNA) was detected in some culture-negative sputum samples. <em>H. influenzae </em>is particularly problematic because <em>Haemophilus haemolyticus</em>, which is not a pathogen, is frequently misidentified as <em>H. influenzae </em>[<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies comparing culture to quantitative polymerase chain reaction (PCR) for the three most common bacterial pathogens (<em>H. influenzae</em>, <em>M. catarrhalis</em>, <em>S. pneumoniae</em>) also demonstrated a doubling of pathogen detection with the latter technique, confirming the low sensitivity of sputum culture [<a href="#rid60">60,61</a>]. However, the detection of these organisms by PCR can be misleading given its high sensitivity and the fact that these organisms can be part of the colonizing oropharyngeal flora.</p><p></p><p class="headingAnchor" id="H2445956044"><span class="h2">Detection of respiratory viruses</span><span class="headingEndMark"> — </span>A key step in evaluating for viral infection is to detect influenza, as it is amenable to antiviral treatment. We therefore test for influenza in all patients with COPD exacerbations when influenza is suspected (eg, during influenza season). Test selection (eg, rapid diagnostic test, PCR) depends on the treatment setting and available resources  (<a class="graphic graphic_table graphicRef69655" href="/d/graphic/69655.html" rel="external">table 3</a>) (see  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>). </p><p>During the pandemic, we test all patients with new or worsening respiratory symptoms, regardless of vaccination status. (See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p>The role of testing for other respiratory viruses in patients with a COPD exacerbation is less clear, as these are not amenable to specific antiviral treatment. PCR-based diagnostic panels that can detect multiple respiratory viruses simultaneously and can be performed in two to three hours in hospital laboratories have been developed [<a href="#rid62">62-66</a>]. Viruses detected by such panels include influenza, adenovirus, parainfluenza virus, respiratory syncytial virus, human metapneumovirus, coronavirus, and rhinovirus [<a href="#rid66">66</a>]. The impact of detection of these viruses (other than influenza) on clinical decision making is minimal, as they can be detected in a stable state, concomitant bacterial infection is not excluded and specific antiviral treatment is not available. We do not routinely use these panels in immunocompetent COPD patients presenting with an exacerbation. (See  <a class="medical medical_review" href="/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease", section on 'Respiratory virus treatment'</a> and  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Other respiratory viruses'</a>.)</p><p class="headingAnchor" id="H1188334769"><span class="h2">Procalcitonin and C-reactive protein</span><span class="headingEndMark"> — </span>Numerous studies have investigated the utility of procalcitonin and C-reactive protein (CRP) to help determine the need for antibiotic therapy in patients with acute exacerbations of COPD [<a href="#rid67">67-72</a>]. However, study results do not clearly and consistently demonstrate that use of either assay adds value to clinical judgment alone.</p><p>In one randomized trial evaluating &gt;650 patients with acute exacerbations of COPD, CRP-guided antibiotic use was associated with a 20 percent decrease in antibiotic use (57 versus 77 percent) when compared with usual care and was not associated with an increase in adverse events [<a href="#rid72">72</a>]. The reduction in antibiotic use was greatest in patients with ≥2 Anthonisen criteria (ie, increased dyspnea, sputum production, and/or sputum purulence). While these findings are compelling, narrow-spectrum antibiotics (ie, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>) were used to treat &gt;75 percent of patients in the study, suggesting that treatment in the usual care arm may have been suboptimal. Standard endpoints, such as treatment failure or relapse within four to eight weeks, were not included in this study. More studies with appropriate endpoints and outcomes are required before we incorporate CRP testing into routine clinical practice.</p><p>Trials evaluating the use of procalcitonin to guide antibiotic use in acute exacerbations of COPD are discussed separately. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Acute exacerbations of chronic obstructive pulmonary disease'</a>.)</p><p class="headingAnchor" id="H122196229"><span class="h2">Chest imaging</span><span class="headingEndMark"> — </span>We generally obtain chest imaging (eg, chest radiograph, computed tomography) for patients with possible acute exacerbation of COPD presenting to the emergency department or in hospital settings to help identify concurrent treatable conditions (eg, pneumonia, heart failure, pneumothorax). Observational studies suggest that findings on chest imaging change management in approximately 11 to 33 percent of patients in this setting [<a href="#rid73">73-78</a>].</p><p>The value of chest imaging in the outpatient setting is less clear. Systematic studies in office-based settings on the utility of chest radiology are not available and are likely to have a low yield. We therefore use clinical judgement to determine the need for chest radiology for outpatients. Clinical suspicion for pneumonia (eg, high fever, toxic appearance, signs of consolidation or pleural effusion) or for heart failure (eg, increased jugular venous pressure, bibasilar crackles, peripheral edema, abnormal heart sounds) are reasonable indications for chest imaging. Dyspnea and chest discomfort, particularly if sudden onset, should raise suspicion and prompt evaluation for pneumothorax or pulmonary embolism.</p><p class="headingAnchor" id="H3627644025"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H3958201541"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of an acute COPD exacerbation</strong> – An exacerbation of chronic obstructive pulmonary disease (COPD) is defined as an event characterized by dyspnea and/or cough and sputum that worsens over ≤14 days, which may be accompanied by tachypnea and/or tachycardia, and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Most exacerbations of COPD are due to respiratory infection. The remaining cases are due to eosinophilic inflammation, environmental pollution, or unknown causes. Respiratory infections that can cause exacerbations include viral, bacterial, and mixed infections. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The three cardinal symptoms that characterize an exacerbation of COPD are increased dyspnea, increased sputum volume and/or viscosity, increased sputum purulence. Other common findings include tachypnea, chest discomfort, fatigue, sleep disturbance, and a decline in pulmonary function. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">In general, patients with more advanced COPD and those with a higher number of cardinal symptoms (particularly sputum purulence) are more likely to have bacterial infections. (See <a class="local">'Features that suggest bacterial infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Determining which patients have a treatable infection and need microbiologic testing is a key part of the evaluation. (See <a class="local">'Evaluation for infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to obtain sputum studies</strong> – For most patients, obtaining sputum Gram stain and culture for microbiologic diagnosis is not necessary. We reserve testing for patients with COPD exacerbations with risk factors for <em>Pseudomonas</em> infection  (<a class="graphic graphic_table graphicRef126162" href="/d/graphic/126162.html" rel="external">table 2</a>), failure to improve on initial empiric antibiotics, and in hospitalized patients (particularly those with impending or actual acute respiratory failure due to an exacerbation of COPD). (See <a class="local">'When to obtain sputum studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testing for respiratory viruses</strong> –<strong> </strong>We test for influenza in all patients with COPD exacerbations when influenza is suspected (eg, the patient presents during influenza season and has a clinical picture suggestive of influenza). (See <a class="local">'Detection of respiratory viruses'</a> above.)</p><p></p><p class="bulletIndent2">During the pandemic, we test all patients with new or worsening respiratory symptoms, regardless of vaccination status. (See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to obtain chest imaging</strong> – We generally obtain chest imaging (eg, chest radiograph, computed tomography) for patients with possible acute exacerbation of COPD presenting to the emergency department or in hospital settings to help identify concurrent treatable conditions (eg, pneumonia, heart failure, pneumothorax). The value of chest imaging in the outpatient setting is less clear. (See <a class="local">'Chest imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of infection in exacerbations of COPD is presented separately. (See  <a class="medical medical_review" href="/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease"</a>.)</p><p></p><p class="headingAnchor" id="H541710557"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Celli BR, Fabbri LM, Aaron SD, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021; 204:1251.</a></li><li><a class="nounderline abstract_t">Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184:662.</a></li><li><a class="nounderline abstract_t">Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax 2006; 61:250.</a></li><li><a class="nounderline abstract_t">Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.</a></li><li><a class="nounderline abstract_t">Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy. Infect Dis Clin North Am 2004; 18:861.</a></li><li><a class="nounderline abstract_t">Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618.</a></li><li><a class="nounderline abstract_t">Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113:465.</a></li><li><a class="nounderline abstract_t">Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58:37.</a></li><li><a class="nounderline abstract_t">Smith CB, Golden CA, Kanner RE, Renzetti AD Jr. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980; 121:225.</a></li><li><a class="nounderline abstract_t">Tan WC, Xiang X, Qiu D, et al. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med 2003; 115:272.</a></li><li><a class="nounderline abstract_t">McNamara MJ, Phillips IA, Williams OB. Viral and Mycoplasma pneumoniae infections in exacerbations of chronic lung disease. Am Rev Respir Dis 1969; 100:19.</a></li><li><a class="nounderline abstract_t">Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:167.</a></li><li><a class="nounderline abstract_t">Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173:1114.</a></li><li><a class="nounderline abstract_t">Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort. Respir Res 2020; 21:77.</a></li><li><a class="nounderline abstract_t">Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749.</a></li><li><a class="nounderline abstract_t">Hamelin ME, Côté S, Laforge J, et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41:498.</a></li><li><a class="nounderline abstract_t">Poole S, Brendish NJ, Clark TW. SARS-CoV-2 has displaced other seasonal respiratory viruses: Results from a prospective cohort study. J Infect 2020; 81:966.</a></li><li><a class="nounderline abstract_t">Chan KPF, Ma TF, Kwok WC, et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med 2020; 171:106085.</a></li><li><a class="nounderline abstract_t">Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2021; 203:24.</a></li><li><a class="nounderline abstract_t">Papadopoulos NG, Bates PJ, Bardin PG, et al. Rhinoviruses infect the lower airways. J Infect Dis 2000; 181:1875.</a></li><li><a class="nounderline abstract_t">Mallia P, Johnston SL. How viral infections cause exacerbation of airway diseases. Chest 2006; 130:1203.</a></li><li><a class="nounderline abstract_t">Bartlett JG. Diagnostic accuracy of transtracheal aspiration bacteriologic studies. Am Rev Respir Dis 1977; 115:777.</a></li><li><a class="nounderline abstract_t">Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142:1004.</a></li><li><a class="nounderline abstract_t">Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498.</a></li><li><a class="nounderline abstract_t">Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316.</a></li><li><a class="nounderline abstract_t">Rosell A, Monsó E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:891.</a></li><li><a class="nounderline abstract_t">Bandi V, Apicella MA, Mason E, et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001; 164:2114.</a></li><li><a class="nounderline abstract_t">Nseir S, Cavestri B, Di Pompeo C, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008; 76:253.</a></li><li><a class="nounderline abstract_t">Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465.</a></li><li><a class="nounderline abstract_t">Murphy TF, Brauer AL, Sethi S, et al. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis 2007; 195:81.</a></li><li><a class="nounderline abstract_t">Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009; 49:124.</a></li><li><a class="nounderline abstract_t">Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:853.</a></li><li><a class="nounderline abstract_t">Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009; 15:138.</a></li><li><a class="nounderline abstract_t">Sethi S, Wrona C, Grant BJ, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:448.</a></li><li><a class="nounderline abstract_t">Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172:195.</a></li><li><a class="nounderline abstract_t">Murphy TF, Brauer AL, Aebi C, Sethi S. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun 2005; 73:8161.</a></li><li><a class="nounderline abstract_t">Bogaert D, van der Valk P, Ramdin R, et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004; 72:818.</a></li><li><a class="nounderline abstract_t">Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:491.</a></li><li><a class="nounderline abstract_t">Chin CL, Manzel LJ, Lehman EE, et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005; 172:85.</a></li><li><a class="nounderline abstract_t">Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:356.</a></li><li><a class="nounderline abstract_t">Mammen MJ, Sethi S. COPD and the microbiome. Respirology 2016; 21:590.</a></li><li><a class="nounderline abstract_t">Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol 2014; 52:2813.</a></li><li><a class="nounderline abstract_t">Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:1224.</a></li><li><a class="nounderline abstract_t">Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J 2016; 47:1082.</a></li><li><a class="nounderline abstract_t">Beaty CD, Grayston JT, Wang SP, et al. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144:1408.</a></li><li><a class="nounderline abstract_t">Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6:19.</a></li><li><a class="nounderline abstract_t">Wilkinson TM, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006; 129:317.</a></li><li><a class="nounderline abstract_t">Bandi V, Jakubowycz M, Kinyon C, et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37:69.</a></li><li><a class="nounderline abstract_t">Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196.</a></li><li><a class="nounderline abstract_t">Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010; 13:965.</a></li><li><a class="nounderline abstract_t">Petty TL. Definitions in chronic obstructive pulmonary disease. Clin Chest Med 1990; 11:363.</a></li><li class="breakAll">American Thoracic Society / European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet]. Version 1.2 http://www.thoracic.org/go/copd (Accessed on October 20, 2011).</li><li><a class="nounderline abstract_t">Soler N, Agustí C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62:29.</a></li><li><a class="nounderline abstract_t">Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117:1638.</a></li><li><a class="nounderline abstract_t">Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2011; 52 Suppl 4:S290.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.</a></li><li><a class="nounderline abstract_t">Garcia-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009; 34:1072.</a></li><li><a class="nounderline abstract_t">Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:266.</a></li><li><a class="nounderline abstract_t">Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67:1075.</a></li><li><a class="nounderline abstract_t">Desai H, Eschberger K, Wrona C, et al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11:303.</a></li><li><a class="nounderline abstract_t">Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010; 138:811.</a></li><li><a class="nounderline abstract_t">Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011; 52 Suppl 4:S326.</a></li><li><a class="nounderline abstract_t">Gaydos CA. What is the role of newer molecular tests in the management of CAP? Infect Dis Clin North Am 2013; 27:49.</a></li><li><a class="nounderline abstract_t">Poritz MA, Blaschke AJ, Byington CL, et al. FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PLoS One 2011; 6:e26047.</a></li><li class="breakAll">BioFire Diagnostics. FilmArray Respiratory Panel. http://www.biofiredx.com/pdfs/FilmArray/InfoSheet,%20FilmArray%20Respiratory%20Panel-0229.pdf (Accessed on October 21, 2014).</li><li><a class="nounderline abstract_t">Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10:CD007498.</a></li><li><a class="nounderline abstract_t">Daubin C, Valette X, Thiollière F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med 2018; 44:428.</a></li><li><a class="nounderline abstract_t">Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev 2017; 26.</a></li><li><a class="nounderline abstract_t">Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9.</a></li><li><a class="nounderline abstract_t">Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Butler CC, Gillespie D, White P, et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. N Engl J Med 2019; 381:111.</a></li><li><a class="nounderline abstract_t">Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Arch Intern Med 1989; 149:2493.</a></li><li><a class="nounderline abstract_t">Jain P, Misra A. Routine chest x-ray in chronic obstructive airways disease: a myth. N Z Med J 1990; 103:163.</a></li><li><a class="nounderline abstract_t">Tsai TW, Gallagher EJ, Lombardi G, et al. Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease. Ann Emerg Med 1993; 22:1854.</a></li><li><a class="nounderline abstract_t">Emerman CL, Cydulka RK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993; 22:680.</a></li><li class="breakAll">Malagari K, Voloudaki A. Radiology of AECOPD. In: Acute Exacerbations of Chronic Obstructive Pulmonary Disease, Siafakis N, Antonisen NR, Georgopoulos D (Eds), CRC Press, Boca Raton, FL 2003. p.161.</li><li class="breakAll">Royal College of Physicians. National COPD Audit 2008 http://www.rcplondon.ac.uk/resources/chronic-obstructive-pulmonary-disease-audit (Accessed on January 17, 2014).</li></ol></div><div id="topicVersionRevision">Topic 108592 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.goldcopd.org" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570991" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21680942" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16517585" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : COPD exacerbations . 2: aetiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038881" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infection in the pathogenesis and course of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15555829" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719299" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1267252" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Role of infection in chronic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511718" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6244766" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967691" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4307732" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Viral and Mycoplasma pneumoniae infections in exacerbations of chronic lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903237" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Respiratory viral infections in adults with and without chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484677" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32228581" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858184" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Respiratory syncytial virus infection in elderly and high-risk adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028158" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33207254" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : SARS-CoV-2 has displaced other seasonal respiratory viruses: Results from a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32917356" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33146552" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837165" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rhinoviruses infect the lower airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035457" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : How viral infections cause exacerbation of airway diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/857717" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnostic accuracy of transtracheal aspiration bacteriologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240819" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603129" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7551388" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851640" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739144" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547944" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181400" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17152011" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480579" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Moraxella catarrhalis, a human respiratory tract pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202344" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pseudomonas aeruginosa in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19532029" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597486" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805178" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16299311" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742525" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079493" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805181" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17478618" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26852737" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : COPD and the microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24850358" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992479" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26917613" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lung microbiome dynamics in COPD exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1741558" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425589" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chlamydia pneumoniae infection in acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16478847" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12770762" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492164" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659270" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205436" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Definitions in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205436" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Definitions in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16928715" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858396" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460287" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699079" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19386694" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117742" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863758" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423399" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20363845" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Respiratory viruses in adults with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460291" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Multiplex PCR and emerging technologies for the detection of respiratory pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398865" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : What is the role of newer molecular tests in the management of CAP?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039434" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039434" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025194" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663044" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143877" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218551" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880285" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31291514" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2818109" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2342680" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Routine chest x-ray in chronic obstructive airways disease: a myth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239107" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8457095" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
